Mcam stabilizes a luminal progenitor-like breast cancer cell state via Ck2 control and Src/Akt/Stat3 attenuation
Balcioglu, O.; Gates, B. L.; Freeman, D. W.; Hagos, B. M.; Mehrabad, E. M.; Ayala-Talavera, D.; Spike, B. T.
Show abstract
Breast cancers are categorized into subtypes with distinctive therapeutic vulnerabilities and prognoses based on their expression of clinically targetable receptors and gene expression patterns mimicking different cell types of the normal gland. Here, we tested the role of Mcam in breast cancer cell state control and tumorigenicity in a luminal progenitor-like murine tumor cell line (Py230) that exhibits lineage and tumor subtype plasticity. Mcam knockdown Py230 cells show augmented Stat3 and Pi3K/Akt activation associated with a lineage state switch away from a hormone-sensing/luminal progenitor state toward alveolar and basal cell related phenotypes that were refractory to growth inhibition by the anti-estrogen therapeutic, tamoxifen. Inhibition of Stat3, or the upstream activator Ck2, reversed these cell state changes. Mcam binds Ck2 and acts as a regulator of Ck2 substrate utilization across multiple mammary tumor cell lines. In Py230 cells this activity manifests as increased mesenchymal morphology, migration, and Src/Fak/Mapk/Paxillin adhesion complex signaling in vitro, in contrast to Mcams reported roles in promoting mesenchymal phenotypes. In vivo, Mcam knockdown reduced tumor growth and take rate and inhibited cell state transition to Sox10+/neural crest like cells previously been associated with tumor aggressiveness. This contrasts with human luminal breast cancers where MCAM copy number loss is highly coupled to Cyclin D amplification, increased proliferation, and the more aggressive Luminal B subtype. Together these data indicate a critical role for Mcam and its regulation of Ck2 in control of breast cancer cell state plasticity with implications for progression, evasion of targeted therapies and combination therapy design. HIGHLIGHTSO_LIMcam is expressed by diverse breast cancer subtypes. C_LIO_LIMcam regulates breast cancer cell state plasticity. C_LIO_LIMcam maintains the mammary luminal progenitor state. C_LIO_LIMcam attenuates Stat activity. C_LIO_LIMcam dictates Ck2 substrate utilization. C_LI
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- An EMT-primary cilium-GLIS2 signaling axis regulates mammogenesis and claudin-low breast tumorigenesis 97%
- Aneuploidy and deregulated DNA damage response define haploinsufficiency in breast tissues of BRCA2 mutation carriers 97%
- Autocrine TGFβ2 enforces a transcriptionally hybrid cell state in Ewing sarcoma 96%
Similar papers in this journal
- Ki-67 promotes sequential stages of tumourigenesis by enabling cellular plasticity 96%
- Interplay between Desmoglein2 and hypoxia controls metastasis in breast cancer 95%
- SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status 94%
Similar papers in this journal
Similar papers in this journal
- Postpartum breast cancer progression is driven by semaphorin 7a mediated invasion and survival 96%
- A SNAI2-PEAK1 stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting a cytokine expression profile that converges on PI3K/Akt signaling 96%
- Isoform-specific functions of Numb in breast cancer progression, metastasis and proteome remodeling. 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.